Research programme: respiratory tract disorders small molecule therapeutics - VecturaAlternative Names: VR 588; VR 611
Latest Information Update: 29 Nov 2016
At a glance
- Originator Vectura
- Class Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors; TRPV1 receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
- Discontinued Cough